Exercise Capacity and Idebenone Intervention in Children and Adolescents With Friedreich Ataxia

Archives of Physical Medicine and Rehabilitation

Volumn 91, Issue 7, 2010, Pages 1044-1050

  Drinkard, Bart E ^a   Keyser, Randall E ^a,e   Paul, Scott M ^a   Arena, Ross ^f   Plehn, Jonathan F ^b   Yanovski, Jack A ^c   Di Prospero, Nicholas A ^d  

^a NATIONAL INSTITUTES OF HEALTH   (United States)

^b NATIONAL HEART LUNG AND BLOOD INSTITUTE   (United States)

^c EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH AND HUMAN DEVELOPMENT   (United States)

^d NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE   (United States)

^e GEORGE MASON UNIVERSITY   (United States)

^f VIRGINIA COMMONWEALTH UNIVERSITY   (United States)

Author keywords

Exercise; Friedreich Ataxia; Idebenone substance name ; Rehabilitation

Indexed keywords

ADENINE; GUANINE; IDEBENONE; PLACEBO;

ABSENCE OF SIDE EFFECTS; ADOLESCENT; ARTICLE; BRAIN FUNCTION; CLINICAL FEATURE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG MEGADOSE; ECHOCARDIOGRAPHY; EXERCISE; FEMALE; FRIEDREICH ATAXIA; HEART LEFT VENTRICLE EJECTION FRACTION; HEART LEFT VENTRICLE WALL; HUMAN; LOW DRUG DOSE; MAJOR CLINICAL STUDY; MALE; NEUROLOGIC EXAMINATION; OXYGEN CONSUMPTION; PHASE 2 CLINICAL TRIAL; RANDOMIZED CONTROLLED TRIAL; TREATMENT DURATION;

ADOLESCENT; ANTIOXIDANTS; CHILD; DEOXYGUANOSINE; DOSE-RESPONSE RELATIONSHIP, DRUG; DOUBLE-BLIND METHOD; EXERCISE TEST; FEMALE; FRIEDREICH ATAXIA; HUMANS; MALE; OXIDATIVE STRESS; OXYGEN CONSUMPTION; UBIQUINONE;

EID: 77953832142     PISSN: 00039993     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.apmr.2010.04.007     Document Type: Article

References (45)

1. Mateo I., Llorca J., Volpini V., Corral J., Berciano J., and Combarros O. Expanded GAA repeats and clinical variation in Friedreich's ataxia. Acta Neurol Scand 109 (2004) 75-78
2. Campuzano V., Montermini L., Molto M.D., et al. Friedreich's ataxia: autosomal recessive disease caused by an intronic GAA triplet repeat expansion. Science 271 (1996) 1423-1427
3. Durr A., Cossee M., Agid Y., et al. Clinical and genetic abnormalities in patients with Friedreich's ataxia. N Engl J Med 335 (1996) 1169-1175
4. Rotig A., de Lonlay P., Chretien D., et al. Aconitase and mitochondrial iron-sulphur protein deficiency in Friedreich ataxia. Nat Genet 17 (1997) 215-217
5. Schulz J.B., Dehmer T., Schols L., et al. Oxidative stress in patients with Friedreich ataxia. Neurology 55 (2000) 1719-1721
6. Lodi R., Cooper J.M., Bradley J.L., et al. Deficit of in vivo mitochondrial ATP production in patients with Friedreich ataxia. Proc Natl Acad Sci U S A 96 (1999) 11492-11495
7. Vorgerd M., Schols L., Hardt C., Ristow M., Epplen J.T., and Zange J. Mitochondrial impairment of human muscle in Friedreich ataxia in vivo. Neuromuscul Disord 10 (2000) 430-435
8. Lodi R., Rajagopalan B., Blamire A.M., et al. Cardiac energetics are abnormal in Friedreich ataxia patients in the absence of cardiac dysfunction and hypertrophy: an in vivo 31P magnetic resonance spectroscopy study. Cardiovasc Res 52 (2001) 111-119
9. Haller R.G. Oxygen utilization and delivery in metabolic myopathies. Ann Neurol 36 (1994) 811-813
10. Taivassalo T., Jensen T.D., Kennaway N., DiMauro S., Vissing J., and Haller R.G. The spectrum of exercise tolerance in mitochondrial myopathies: a study of 40 patients. Brain 126 Pt 2 (2003) 413-423
11. Schols L., Meyer C., Schmid G., Wilhelms I., and Przuntek H. Therapeutic strategies in Friedreich's ataxia. J Neural Transm Suppl 68 (2004) 135-145
12. Gillis J.C., Benefield P., and McTavish D. Idebenone. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic use in age-related cognitive disorders. Drugs Aging 5 (1994) 133-152
13. Lodi R., Hart P.E., Rajagopalan B., et al. Antioxidant treatment improves in vivo cardiac and skeletal muscle bioenergetics in patients with Friedreich's ataxia. Ann Neurol 49 (2001) 590-596
14. Schols L., Vorgerd M., Schillings M., Skipka G., and Zange J. Idebenone in patients with Friedreich ataxia. Neurosci Lett 306 (2001) 169-172
15. Mariotti C., Solari A., Torta D., Marano L., Fiorentini C., and Di Donato S. Idebenone treatment in Friedreich patients: one-year-long randomized placebo-controlled trial. Neurology 60 (2003) 1676-1679
16. Rustin P., Rotig A., Munnich A., and Sidi D. Heart hypertrophy and function are improved by idebenone in Friedreich's ataxia. Free Radic Res 36 (2002) 467-469
17. Artuch R., Aracil A., Mas A., et al. Friedreich's ataxia: idebenone treatment in early stage patients. Neuropediatrics 33 (2002) 190-193
18. Di Prospero N.A., Sumner C.J., Penzak S.R., Ravina B., Fischbeck K.H., and Taylor J.P. Safety, tolerability, and pharmacokinetics of high-dose idebenone in patients with Friedreich ataxia. Arch Neurol 64 (2007) 803-808
19. Di Prospero N.A., Baker A., Jeffries N., and Fischbeck K.H. Neurological effects of high-dose idebenone in patients with Friedreich's ataxia: a randomised, placebo-controlled trial. Lancet Neurol 6 (2007) 878-886
20. Trouillas P., Takayanagi T., Hallett M., et al. International Cooperative Ataxia Rating Scale for pharmacological assessment of the cerebellar syndrome. The Ataxia Neuropharmacology Committee of the World Federation of Neurology. J Neurol Sci 145 (1997) 205-211
21. Subramony S.H., May W., Lynch D., et al. Measuring Friedreich ataxia: interrater reliability of a neurologic rating scale. Neurology 64 (2005) 1261-1262
22. Lang R.M., Bierig M., Devereux R.B., et al. Recommendations for chamber quantification. Eur J Echocardiogr 7 (2006) 79-108
23. Devereux R.B., Alonso D.R., Lutas E.M., et al. Echocardiographic assessment of left ventricular hypertrophy: comparison to necropsy findings. Am J Cardiol 57 (1986) 450-458
24. de Simone G., Daniels S.R., Kimball T.R., et al. Evaluation of concentric left ventricular geometry in humans: evidence for age-related systematic underestimation. Hypertension 45 (2005) 64-68
25. Kasner M., Westermann D., Steendijk P., et al. Utility of Doppler echocardiography and tissue Doppler imaging in the estimation of diastolic function in heart failure with normal ejection fraction: a comparative Doppler-conductance catheterization study. Circulation 116 (2007) 637-647
26. Richard R., Lonsdorfer-Wolf E., Charloux A., et al. Non-invasive cardiac output evaluation during a maximal progressive exercise test, using a new impedance cardiograph device. Eur J Appl Physiol 85 (2001) 202-207
27. Charloux A., Lonsdorfer-Wolf E., Richard R., et al. A new impedance cardiograph device for the non-invasive evaluation of cardiac output at rest and during exercise: comparison with the "direct" Fick method. Eur J Appl Physiol 82 (2000) 313-320
28. Greenberg B.H., Hermann D.D., Pranulis M.F., Lazio L., and Cloutier D. Reproducibility of impedance cardiography hemodynamic measures in clinically stable heart failure patients. Congest Heart Fail 6 (2000) 74-80
29. Hirschl M.M., Kittler H., Woisetschlager C., et al. Simultaneous comparison of thoracic bioimpedance and arterial pulse waveform-derived cardiac output with thermodilution measurement. Crit Care Med 28 (2000) 1798-1802
30. Welsman J., Bywater K., Farr C., Welford D., and Armstrong N. Reliability of peak VO(2) and maximal cardiac output assessed using thoracic bioimpedance in children. Eur J Appl Physiol 94 (2005) 228-234
31. Rowland T.W. Developmental exercise physiology (1996), Human Kinetics, Champaign
32. Drinkard B., Roberts M.D., Ranzenhofer L.M., et al. Oxygen-uptake efficiency slope as a determinant of fitness in overweight adolescents. Med Sci Sports Exerc 39 (2007) 1811-1816
33. Cooper D.M., Weiler-Ravell D., Whipp B.J., and Wasserman K. Aerobic parameters of exercise as a function of body size during growth in children. J Appl Physiol 56 (1984) 628-634
34. Ainsworth B.E., Haskell W.L., Whitt M.C., et al. Compendium of physical activities: an update of activity codes and MET intensities. Med Sci Sports Exerc 32 9 Suppl (2000) S498-S504
35. Rowland T.W. Effect of prolonged inactivity on aerobic fitness of children. J Sports Med Phys Fitness 34 (1994) 147-155
36. Capelli C., Antonutto G., Kenfack M.A., et al. Factors determining the time course of VO2(max) decay during bedrest: implications for VO2(max) limitation. Eur J Appl Physiol 98 (2006) 152-160
37. Plehn J.F.H.K., H K., Horton K., Ernst I., Arai A.E., and DiProspero N.A. Short-term effects of high dose idebenone on left ventricular mass and function in a pediatric cohort with Friedreich's ataxia. Circulation 118 Suppl 2 (2008) S799 [abstract]
38. Kitzman D.W., Higginbotham M.B., Cobb F.R., Sheikh K.H., and Sullivan M.J. Exercise intolerance in patients with heart failure and preserved left ventricular systolic function: failure of the Frank-Starling mechanism. J Am Coll Cardiol 17 (1991) 1065-1072
39. Pianosi P.T. Measurement of exercise cardiac output by thoracic impedance in healthy children. Eur J Appl Physiol 92 (2004) 425-430
40. Vinet A., Nottin S., Lecoq A.M., and Obert P. Cardiovascular responses to progressive cycle exercise in healthy children and adults. Int J Sports Med 23 (2002) 242-246
41. Lynch D.R., Lech G., Farmer J.M., et al. Near infrared muscle spectroscopy in patients with Friedreich's ataxia. Muscle Nerve 25 (2002) 664-673
42. Rustin P., von Kleist-Retzow J.C., Chantrel-Groussard K., Sidi D., Munnich A., and Rotig A. Effect of idebenone on cardiomyopathy in Friedreich's ataxia: a preliminary study. Lancet 354 (1999) 477-479
43. Zhang Y.Y., Johnson II M.C., Chow N., and Wasserman K. Effect of exercise testing protocol on parameters of aerobic function. Med Sci Sports Exerc 23 (1991) 625-630
44. Fillyaw M.J., and Ades P.A. Endurance exercise training in Friedreich ataxia. Arch Phys Med Rehabil 70 (1989) 786-788
45. Ilg W., Synofzik M., Brotz D., Burkard S., Giese M.A., and Schols L. Intensive coordinative training improves motor performance in degenerative cerebellar disease. Neurology 73 (2009) 1823-1830